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Summary
Accurate pathological diagnosis is crucial for optimal management of cancer patients. For the 
~100 known central nervous system (CNS) tumour entities, standardization of the diagnostic 
process has been shown to be particularly challenging - with substantial inter-observer variability 
in the histopathological diagnosis of many tumour types. We herein present the development of a 
comprehensive approach for DNA methylation-based CNS tumour classification across all entities 
and age groups, and demonstrate its application in a routine diagnostic setting. We show that 
availability of this method may have substantial impact on diagnostic precision compared with 
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standard methods, resulting in a change of diagnosis in up to 12% of prospective cases. For 
broader accessibility we have designed a free online classifier tool 
(www.molecularneuropathology.org) requiring no additional onsite data processing. Our results 
provide a blueprint for the generation of machine learning-based tumour classifiers across other 
cancer entities, with the potential to fundamentally transform tumour pathology.
The developmental complexity of the brain is reflected in the vast array of distinct brain 
tumour entities defined in the current WHO classification of central nervous system (CNS) 
tumours 1. These tumours are clinically and biologically highly diverse, encompassing a 
wide spectrum from benign neoplasms that can frequently be cured by surgery alone (e.g. 
pilocytic astrocytoma), to highly malignant tumours responding poorly to any therapy (e.g. 
glioblastoma). Previous studies reported substantial inter-observer variability in the 
histopathological diagnosis of many CNS tumours, e.g., in diffuse gliomas 2, ependymomas 
3
 and supratentorial PNETs 4. To address this, some molecular grouping has been introduced 
into the update of the WHO classification, but only for selected entities such as 
medulloblastoma. Furthermore, several single-gene tests based on DNA methylation 
analysis (e.g., MGMT promoter methylation status), FISH (e.g., 1p/19q, EGFR, MYC, 
MYCN, PDGFRA, 19q13.42, etc.) or immunohistochemistry (CTNNB1, LIN28A, etc.) that 
are required to cover the most important differential diagnoses have been shown to be 
difficult to standardize. Such diagnostic discordance and uncertainty may confound 
decision-making in clinical practice as well as the interpretation and validity of clinical trial 
results.
The cancer methylome is a combination of both somatically acquired DNA methylation 
changes and characteristics reflecting the cell of origin 5,6. The latter property allows, for 
example, tracing of the primary site of highly dedifferentiated metastases of cancers of 
unknown origin 7. It has been convincingly shown that DNA methylation profiling is highly 
robust and reproducible even from small samples and poor quality material 8, and such 
profiles have been widely used to subclassify CNS tumours that were previously considered 
homogeneous diseases 4,9–16. Based on this preliminary work within single entities, we 
herein present a comprehensive approach for DNA methylation-based classification of all 
CNS tumour entities across age groups.
CNS tumour reference cohort
To establish a comprehensive CNS tumour reference cohort, we generated genome-wide 
DNA methylation profiles (minimum of eight cases per group) representing almost all WHO 
defined neuroectodermal and sellar region tumours 1. We further profiled mesenchymal 
tumours, melanoma, diffuse large B-cell lymphoma, plasmacytoma and six types of pituitary 
adenomas, in total comprising 76 histopathological entities and seven entity variants 
occurring in the CNS. All histopathological entities and variants were analysed by 
unsupervised clustering both within each entity and across histologically similar tumour 
entities, aiming to identify (i) distinct DNA methylation classes within one histopathological 
entity and (ii) DNA methylation classes comprising tumours displaying a varied histological 
phenotype. This iterative process led to the designation of 82 CNS tumour classes 
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characterised by distinct DNA methylation profiles (Figure 1a). Twenty-nine of these were 
equivalent to a single WHO entity (category 1), 29 represented subclasses within a WHO 
entity (category 2), in eight the WHO grading was not fully recapitulated (category 3) and in 
11 the boundaries of methylation classes were not identical to the entity boundaries of WHO 
(category 4) (Figure 1a). The remaining five represented DNA methylation classes not 
defined by the WHO classification (category 5), three of which were recently described 4 as 
well as the not yet well-defined class of anaplastic pilocytic astrocytoma and one new 
subclass of infantile hemispheric glioma. There was evidence for several additional classes 
of rare tumours, with too few cases to be included at present. In consideration of the impact 
of the tumour microenvironment on the methylation profile, we included 47 tumour samples 
with a pronounced inflammatory or reactive tumour microenvironment, respectively, both 
demonstrating distinct methylation profiles. We additionally selected 72 samples 
representing seven non-neoplastic CNS regions, resulting in a combined reference cohort of 
2,801 samples from 91 classes (Figure 1a) that was visualized using t-SNE dimensionality 
reduction 17 (Figure 1b). This analysis further supported the separation of samples into the 
defined DNA methylation classes (see also Extended Data Figure 1a, b; unprocessed .idat 
files can be downloaded at NCBIs Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo), accession number GSE90496). Supplementary Table 1 gives an 
overview of methylation class characteristics and Supplementary Table 2 shows case-by-
case information of the reference samples.
The stability of separation of methylation classes by t-SNE was analysed by iterative random 
downsampling of the reference cohort and indicated a high stability of the groups (Extended 
Data Figure 1c, d). Testing for confounding batch effects within our reference cohort did not 
reveal unexpected confounding factors (Extended Data Figure 2, Extended Data Figure 3a-
c). For reference astrocytomas, oligodendrogliomas and glioblastomas we performed 
additional classification according to the TCGA pan glioma DNA methylation model18 
indicating a strong association of the TCGA classes LGm1–6 with specific classes defined 
in our reference cohort (Extended Data Figure 3d, Supplementary Table 2).
Classifier development
Application in routine diagnostics requires fast and reproducible classification of samples as 
well as a measure of confidence for the specific call. To this end, we employed the Random 
Forest (RF) algorithm that is a so called ensemble method that combines the predictions of 
several ‘weak’ classifiers to achieve improved prediction accuracy19. Using this algorithm, 
we generated 10,000 binary decision trees, incorporating genome-wide information from all 
2,801 reference samples and 91 methylation classes (Extended Data Figure 4). Each of these 
trees assigns a given diagnostic sample to one of the 91 classes, resulting in an aggregate 
raw score (Figure 2a). To obtain class probability estimates that can be used to guide 
diagnostic decision-making, we fitted a multinomial logistic regression calibration model 
that transforms the raw score into a probability that measures the confidence in the class 
assignment (‘calibrated score’). The calibration allows a comparison of classifier results 
between classes despite a different raw score distribution (Extended Data Figure 5a, b). 
Cross-validation of the RF classifier resulted in an estimated error rate of 4.89% for raw and 
4.28% for calibrated scores and an area under receiver operating characteristic curve (AUC) 
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of 0.99, indicating a high discriminating power (Figure 2b, Extended Data Figure 5c). The 
vast majority of cross-validation misclassifications occurred within eight groups of 
histologically and biologically closely related tumour classes, distinction of which is 
currently without clinical impact (with the possible exception of choroid plexus tumours 13; 
Figure 2b). We therefore defined eight ‘methylation class families’ (MCF), for which 
calibrated scores are summed up to a single score. This reduced the cross-validated error rate 
for the clinically relevant groupings to 1.14% (Figure 2b, Extended Data Figure 5c). Taking 
the maximum score for class assignment and using a multiclass approach 20, overall 
sensitivity and specificity was 0.989 and 0.999, respectively (Extended Data Figure 5c).
For application to diagnostic tumour samples, a threshold value for the prediction of a 
matching class is required. Using Receiver Operating Characteristic (ROC) curve analysis of 
the maximum calibrated scores we devised an optimal “common” calibrated score threshold 
of ≥0.9 (Extended Data Figure 5d, e). For subclasses within methylation class families, we 
defined a threshold value of ≥0.5 as sufficient for a valid prediction, as long as all family 
member scores add up to a total score of ≥0.9. Single class specificity and sensitivity for the 
≥0.9 threshold are provided in Supplementary Table 3.
Clinical implementation
For evaluation of clinical utility, we prospectively analysed a series of 1,155 diagnostic CNS 
tumours in parallel with standard histopathological workup (Figure 3a, b). For 51 cases (4%) 
the material was not suitable for methylation profiling, mostly because of too low tumour 
cell content or limited total material. Methylation profiling was performed for the remaining 
1,104 samples and the cases were assigned as either ‘matching to a defined DNA 
methylation class’ (calibrated score ≥0.9) or as ‘no match’ cases (highest score <0.9) (for a 
case-by-case list see Supplementary Table 4). The investigated cases comprised 64 different 
histopathological entities from both adult (71%) and paediatric patients (29%). The 
spectrum of entities was enriched for rare and difficult to diagnose cases received for 
referral, and therefore did not exactly match the distribution seen in daily routine diagnostic 
practice. Histopathological evaluation was performed blinded to DNA methylation profiling 
results and included standard molecular testing.
In total, 88% of profiled samples (n=977/1,104) matched to an established DNA methylation 
class with a calibrated classifier score ≥0.9 (Figure 3b). For 838 of these (838/1,104; 76%), 
results obtained by pathology and DNA methylation profiling were concordant. In 171 of the 
cases, an unambiguous molecular subgroup could be assigned, which would not have been 
available based on histopathology evaluation only (e.g., molecular subgroups of 
medulloblastoma and ependymoma, many of which were included in the latest version of the 
WHO classification of CNS tumours 1).
For the remaining 139 samples with a calibrated classifier score ≥0.9, the DNA methylation 
class was discordant from the pathological diagnosis. These cases were histologically and 
molecularly re-evaluated, including additional molecular diagnostics (DNA copy-number 
profiling, targeted gene sequencing, gene panel sequencing21, and gene fusion analysis of a 
subset of cases, see Supplementary Table 5). This resulted in a revision of the initial 
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histopathological diagnosis in 129 of the 139 cases (12% of all cases, Figure 4) in favour of 
the predicted methylation class. In agreement with several recent reports 16,22,23, several of 
these were IDH-wildtype astrocytomas and anaplastic astrocytomas reclassified as IDH-
wildtype glioblastomas. Establishing a new diagnosis had a profound clinical impact: a 
change in WHO grading was observed in 71% of these cases (92/129), with both upgrading 
(41%, 53/129) and downgrading (30%, 39/129; Figure 4). Discrepant results could not be 
resolved in only 10 cases (<1% of profiled cases), and the histopathological diagnosis was 
retained.
To substantiate the impact in clinical practice we contacted five external centres that have 
started to implement methylation profiling for diagnostic cases using our algorithm. In total, 
these centres analysed 401 diagnostic cases and in 50 cases (12%) a new diagnosis was 
established after methylation profiling, very closely recapitulating our rate of reclassification 
(Extended Data Figure 6a, Supplementary Table 6). For individual centres the rate of 
reclassification varied between 6% and 25%, most likely due to differences of the spectrum 
of investigated cases and more upfront molecular testing by some centres (Extended Data 
Figure 6b, Supplementary Table 6).
Twelve percent of tumours from the prospective cohort (127/1,104) could not be assigned to 
a DNA methylation class using the rigid calibrated classifier score cutoff of ≥0.9 (Figure 
3b). To further clarify the role of these non-classifiable cases we performed an unsupervised 
t-SNE analysis of the reference cohort together with the diagnostic cohort (Figure 5a). This 
demonstrated a high overlap of the classifiable cases with the reference cohort, whereas non-
classifiable cases frequently fell in the periphery of the reference classes or even completely 
separate from these and frequently grouped with other non-classifiable cases (Figure 5a). 
This may indicate that such cases represent rare novel molecular entities that have not been 
previously recognized. An example for a likely novel CNS tumour entity is exemplified in 
Figure 5b, c.
Technical and inter-laboratory testing
Technical robustness of the RF classifier was investigated by inter-laboratory comparison. 
Results of two independent laboratories (starting from DNA extraction) were highly 
correlated, with only two of 53 samples (4%) showing a classifier score slightly lower than 
0.9 in one of the centres whereas all other cases were classified identically (Extended Data 
Figure 7a). Calculation of copy number profiles was also stable across laboratories 
(Extended Data Figure 7b). To ascertain forward compatibility with developing 
technologies, we further used the RF classifier to interrogate newer EPIC DNA methylation 
arrays and high-coverage whole-genome bisulfite sequencing data. For all 16 samples from 
different CNS tumours profiled on both array platforms, raw scores (Extended Data Figure 
7c) and calibrated scores (not shown) were highly correlated and running them through the 
classifying algorithm resulted in the same prediction for every case. Further, for all 50 high-
coverage whole-genome bisulfite sequencing samples (11 different CNS tumour entities), 
the highest prediction score was for the same class as with the 450k array, suggesting that 
our approach is applicable to different DNA methylation profiling techniques with only 
slight adaptations (Extended Data Figure 7d).
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Global dissemination of the platform
To ensure unrestricted community access to our classification system, we created a free web 
platform for data upload, automatic normalization, Random Forest classification, and PDF 
report generation (www.molecularneuropathology.org). DNA copy-number profiles24 and 
O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status25 are 
additionally provided, since they can be generated from the same data source – thus having 
the potential of replacing several time- and cost-intensive single-gene tests. A representative 
website report is shown in Extended Data Figure 8. During upload, the data provider can 
chose to give consent that the data may be used for further classifier development. We expect 
that this web platform can thereby act as a hub for a worldwide cooperative network to 
continuously identify and track rare tumour classes so that they can eventually be added to 
the catalogue of known human cancers. Since the launch of the website 14 months ago in 
December 2016, over 4,500 cases have been uploaded from over 15 participating centres. 
New biological insights are also likely to be gained based on the interrelationships of tumour 
classes, and by closer examination of how differential DNA methylation affects tumour 
biology.
Discussion
We here demonstrate that DNA methylation-based CNS tumour classification using a 
comprehensive machine learning approach is a valuable asset for clinical decision making. 
In particular, the high level of standardization has great promise to reduce the substantial 
inter-observer variability observed in current CNS tumor diagnostics. Further, in contrast to 
traditional pathology, whereby there is a pressure to assign all tumours to a described entity 
even for atypical or challenging cases, the objective measure that we provide here allows for 
‘no match’ to a defined class. This information can also be of substantial value in 
highlighting that a tumour is not a typical example of a given differential diagnosis, and may 
rather belong to a rarer, yet undefined class. We defined 5 categories of methylation classes 
that have different clinical implications. Category 1 can be directly translated to WHO 
entities. Category 2 represents subclasses of WHO entities. For all but ependymal tumours, 
subclassification currently has little clinical consequence and a translation back to the WHO 
class may be appropriate for clinical purposes. Category 3 reflects the fact that WHO 
grading cannot be fully recapitulated by methylation profiling for several classes. Further 
data is required to assess if the methylation classes of this category may provide a more 
robust means of prognostication than histology alone, as has been demonstrated for several 
other classes 4,9,11. In category 4, the WHO entity boundaries are not identical to the 
boundaries of the methylation classes. Until additional data on the exact boundaries become 
available, this category should be critically discussed in the clinical context and orthogonal 
testing should be undertaken whenever possible. Category 5 represents putative new entities 
that are currently not recognized by the WHO, and while limited data on these cases is 
currently available, the biological rationale for a novel class was considered strong.
A study in which reference pathology and molecular diagnostics including DNA 
methylation profiling are blinded for each other´s results is currently ongoing for all 
childhood brain tumours diagnosed in Germany to objectivise the potential effect of re-
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classification on patient outcome (http://pediatric-neurooncology.dkfz.de/index.php/en/
diagnostics/molecular-neuropathology), with results due over the next few years.
A uniform implementation of the classification algorithm holds great promise for 
standardization of tumour diagnostics across centres and across clinical trials. Further, the 
digital nature of methylation data facilitates easy exchange and will allow aggregation of 
extensive tumour libraries. This will likely result in the detection of exceptionally rare 
tumour classes and a continued refinement of classifiers. Inclusion of new classes will allow 
a prompt translation into diagnostic practice, almost certainly resulting in a more dynamic 
tumour classification. In our experience, adaptation of this technique in diagnostic 
laboratories is relatively straightforward. Extended Data Figure 9 summarizes a sample 
workflow for diagnostic implementation. We expect that the principle of using DNA 
methylation signatures as part of a combined histo-molecular tumour classification will 
improve diagnostic accuracy not only in neuropathology, but will serve as a blueprint in 
other fields of tumour pathology
Methods (online only)
Patient material
Patient material and clinical data of the retrospective reference cohort (total n=2,801) were 
obtained from the National Center for Tumour Diseases (NCT) in Heidelberg and 
supplemented with samples from additional centres (Supplementary Table 2) according to 
protocols approved by the institutional review boards with written consent obtained from 
each patient. Tumours were histopathologically re-assessed according to the current WHO 
classification1. Areas with highest tumour cell content (≥70%) were selected for DNA 
extraction. Subsets of the reference cohort have been previously published4,9–16,26–33. 
Additional patient characteristics are given in Supplementary Table 2. The prospectively 
assessed clinical cohort was analysed as part of the National Center for Tumour Diseases 
Precision Oncology Program according to procedures approved by the institutional review 
board at the Medical Faculty Heidelberg. All patients gave written consent for diagnostic 
procedures, comprising onward molecular testing including methylation profiling. 
Additional patient characteristics are given in Supplementary Table 4. Details of the online-
analysed cohort of the five additional centres are given in Supplementary Table 6. Usage of 
the data was according to protocols approved by the institutional review boards of the 
University of Basel, Frankfurt am Main University Hospital, University Medical Center 
Utrecht and Princess Máxima Center for Pediatric Oncology Utrecht, Giessen University 
Hospital and University College London Hospitals. All patients gave written consent for 
diagnostic procedures, comprising onward molecular testing including methylation profiling. 
For all the above human research participants all relevant ethical regulations were followed.
Data generation, processing and Random Forest classifier generation
Samples were analysed using Illumina Infinium HumanMethylation450 BeadChip (450k) 
arrays according to the manufacturer’s instructions. To investigate stability across platforms 
a selection of samples were additionally assessed using the successor Methylation BeadChip 
(EPIC) array or whole-genome bisulfite sequencing (WGBS, generated and analysed as 
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described6). Array data analysis was performed using R version 3.2.0 34, using a number of 
packages from Bioconductor35 and other repositories. A Random Forest19 classifier 
compatible with both 450k and EPIC platforms was trained, and a calibration model that 
calculates class probabilities from Random Forest scores was devised. A detailed description 
of all methods is provided below.
Methylation array processing
The 450k array was used to obtain genome-wide DNA methylation profiles for tumour 
samples and normal control tissues, according to the manufacturer’s instructions (Illumina, 
San Diego, USA). DNA methylation data was generated at the Genomics and Proteomics 
Core Facility of the DKFZ (Heidelberg, Germany) and the NYU Langone Medical Center 
(New York, USA). Data was generated from both fresh-frozen and formalin-fixed paraffin-
embedded (FFPE) tissue samples. For most fresh-frozen samples, >500 ng of DNA was used 
as input material. 250 ng of DNA was used for most FFPE tissues. On-chip quality metrics 
of all samples were carefully controlled. Copy-number variation (CNV) analysis from 450k 
methylation array data was performed using the conumee Bioconductor package version 
1.3.0. Two sets of 50 control samples displaying a balanced copy-number profile from both 
male and female donors were used for normalization.
Raw signal intensities were obtained from IDAT-files using the minfi Bioconductor package 
version 1.14.0 36. Each sample was individually normalized by performing a background 
correction (shifting of the 5 % percentile of negative control probe intensities to 0) and a 
dye-bias correction (scaling of the mean of normalization control probe intensities to 
10,000) for both colour channels. Subsequently, a correction for the type of material tissue 
(FFPE/frozen) was performed by fitting univariate, linear models to the log2-transformed 
intensity values (removeBatchEffect function, limma package version 3.24.15). The 
methylated and unmethylated signals were corrected individually. Estimated batch effects 
were also used to adjust diagnostic samples or test samples within the cross-validation. Beta-
values were calculated from the retransformed intensities using an offset of 100 (as 
recommended by Illumina). To analyse for possible confounding batch effects within our 
pre-processed reference cohort dataset (after adjusting for FFPE versus frozen material) we 
applied the sva algorithm 37,38. We found no significant surrogate variable (data not shown).
The following filtering criteria were applied: Removal of probes targeting the X and Y 
chromosomes (n=11,551), removal of probes containing a single-nucleotide polymorphism 
(dbSNP132 Common) within five base pairs of and including the targeted CpG site 
(n=7,998), probes not mapping uniquely to the human reference genome (hg19) allowing for 
one mismatch (n=3,965), and probes not included on the Illumina EPIC array (n=32,260). In 
total, 428,799 probes targeting CpG sites were kept for further analysis.
Unsupervised analysis
Pairwise Pearson correlation was calculated for all 2,801 reference samples by selecting the 
32,000 most variably methylated probes (s.d. > 0.228, Extended Data Figure 1a). The same 
probes were used for principal component analysis (PCA). For PCA, pairwise probe 
covariances of centred beta-values were calculated. Eigenvalue decomposition was 
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performed using the eigs function of the RSpectra package version 0.12. The number of non-
trivial components was determined by comparing eigenvalues to the maximum eigenvalue of 
a PCA using randomized beta-values (shuffling of sample labels per probe) (Extended Data 
Figure 1b). Principal component scores for all non-trivial components (n=94) were used for 
t-SNE analysis (t-Distributed Stochastic Neighbour Embedding17, Rtsne package version 
0.11, Figure 1b). The following non-default parameters were used: theta=0, pca=F, 
max_iter=2500. A similar approach was used for the combined analysis of reference and 
diagnostic cases (Figure 5a).
The Random Forest algorithm
The Random Forest (RF) 19 algorithm is a so-called ensemble method that combines the 
predictions of several ‘weak’ classifiers to achieve improved prediction accuracy. The RF 
algorithm uses binary decision trees (Classification and Regression Trees, CART39) as 
‘weak’ classifiers (Extended Data Fig. 4). Each of these trees is a sequence of binary 
splitting rules that are learned by recursive binary splitting. The CART algorithm starts with 
all samples assigned to a ‘root’ node and tries to find the variable, e.g., a measured CpG 
probe, and a corresponding cutoff that results in the purest split into the different classes. To 
measure this gain in class ‘purity’ the Gini index is used. To fit a tree, the CART algorithm 
iteratively repeats these steps until no further improvements can be made. To predict the 
class of a new diagnostic case the binary splitting rules are compared with the new data 
starting in the root node down to one of the leaf nodes. The tree then predicts or votes for the 
class of that leaf node. Decision trees have the advantage that they are non-parametric and 
do not rely on any distributional assumptions. The main disadvantages of decision trees is 
that they often tend to overfit the data and that they have a weak prediction performance. To 
improve the prediction accuracy the RF algorithm combines thousands of trees by bootstrap 
aggregation (bagging). In brief, each tree is fitted using training datasets that are generated 
by drawing bootstrap samples. In addition, at each node only a random subset of the 
available variables is used to find an optimal splitting rule. This additional source of 
randomization allows selecting variables with lower predictive value. This feature 
guarantees that the resulting trees are decorrelated, i.e., they use different variables to find an 
optimal prediction rule. Taking the majority vote over thousands of bootstrap aggregated and 
decorrelated trees greatly improves the prediction accuracy of the RF. The majority vote, i.e., 
the proportion of trees voting for a class, can be interpreted as empirical class probabilities.
Classifier development
To train the RF classifier, the randomForest R package 40 was used. First, the most important 
features (probes) were selected by applying the Random Forest algorithm to the beta-values 
of all filtered 428,799 probes. For efficient computation, the probes were split into 43 sets of 
approximately 10,000 probes. For each set, 100 trees were fitted using 654 randomly 
sampled candidate features at each split (mtry parameter, square root of 428,799, as would 
be used by default when not splitting into sets). To take the imbalanced methylation class 
sizes into account a downsampling strategy was followed that ensures an identical number of 
samples per class (parameter sampsize=rep(8, 91)), eight reflecting the minimum number of 
cases in the 91 classes) 41. For all other parameters the default settings were used. This 
procedure was repeated 100 times, essentially fitting 10,000 trees per probe. Finally, features 
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are selected by the permutation-based variable importance measure as implemented in the 
randomForest R package40. The importance measure is the class-specific mean decrease in 
classification accuracy when the feature is permutated. We select features by ranking them 
using the minimal rank of the variable importance measures across all classes.
The final RF classifier was trained by fitting 10,000 trees with the parameter mtry=100 using 
beta-values of the 10,000 probes selected during feature selection. Imbalanced class sizes 
were accounted for by downsampling (as described above), and for all other parameters the 
default settings were used. An overview of the processes is given in Extended Data Fig. 4.
Classifier cross-validation
Overfitting of the training data is a typical problem expected when training classifiers on 
high-dimensional data. As it often cannot be avoided, the typical strategy to deal with this 
problem is to evaluate the model accuracy on an independent test dataset or apply cross-
validation methods42. Because some of the newly defined methylation groups presented in 
this work cannot be diagnosed by classical histopathological methods or other established 
molecular assays, an independent test set to assess model accuracy is not available. 
Therefore, the accuracy of the presented RF model with the accompanying calibration model 
was evaluated by a three-fold, nested cross-validation (CV). For this, the reference dataset is 
split into three equally sized parts. In each CV iteration, two-thirds of the data were used to 
train a RF classifier in the same way as the RF classifier for the complete dataset was 
trained. Then, the remaining one-third of the data is predicted using this RF classifier. After 
the third iteration of the CV is completed, each of the 2,801 reference samples has been 
predicted by an independent RF classifier, i.e. where the sample was not used for estimating 
batch effects, performing variable selection, or training of the classifier.
Classifier score calibration
The classification scores generated by our multiclass RF (i.e. the proportion of trees voting 
for a class) perform well when they are used to assign the correct class labels, but they do 
not reflect class probabilities. Furthermore, the distribution of the RF scores varies between 
classes, which makes an inter-class comparison difficult. Moreover, to evaluate a diagnostic 
classification, the uncertainties associated with an individual prediction in terms of 
confidence scores or estimated class probabilities are needed.
To obtain scores that are comparable between classes and that are improved estimates of the 
certainty of individual predictions we performed a classification score recalibration by 
mapping the original scores to more accurate class probabilities43,44. To find such a 
mapping, a L2-penalized, multinomial, logistic regression-model was fitted, which takes the 
methylation class as response variable and the RF scores as explanatory variables. The R 
package glmnet45 was used to fit this model. In addition, the model was fitted by 
incorporating a small ridge-penalty (L2) on the likelihood to prevent from over fitting, as 
well as to stabilize estimation in situations where classes are perfectly separable. The 
amount of this regularization, i.e. the penalization parameter, is determined by running a ten-
fold cross-validation and choosing the largest value that lies within one standard error of the 
minimum cross-validation error. Independent RF scores are needed to fit this model, i.e. the 
Capper et al. Page 10
Nature. Author manuscript; available in PMC 2018 September 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
scores need to be generated by a RF classifier that was not trained using the same samples, 
otherwise the RF scores will be systematically biased and not comparable to scores of 
unseen cases. As such, RF scores generated by the three-fold CV are used.
To validate the class predictions generated by using the recalibrated scores of the calibration 
model, a nested three-fold CV loop is incorporated into the main three-fold CV that 
validates the RF classifier (Extended Data Fig. 4). Within each CV run this nested three-fold 
CV is applied to generate independent RF scores, which are then used to train a calibration 
model. The predicted RF scores resulting from predicting the one-third test data of the outer 
CV loop are then recalibrated by applying the calibration model that was fitted on the RF 
scores generated during the nested CV. A similar CV scheme was used by Appel et al.46 to 
validate estimated classification probabilities.
Classifier performance measures
Performances of the resulting classifier predictions and scores generated by the CV were 
assessed by the misclassification error, multiclass area under the curve (AUC) and the 
multiclass Brier score. The misclassification error measures the frequency of falsely 
assigned class labels when using the maximum of the RF scores or re-calibrated scores as a 
cutoff to determine the predicted class, i.e. the majority vote. To measure the AUC for our 
multiclass RF the generalization of the AUC for multiclass classification problems by Hand 
and Till47 was used. To measure how well the resulting RF scores and recalibrated scores 
perform when used as class probabilities, the multiclass Brier Score42,48,49 was used. The 
Brier score is the mean-squared difference between the actual and the predicted class 
probability and thus measures the same characteristic as the mean squared error (MSE) 
measures for a continuous forecast.
Methylation class families
We observed that the majority of misclassification errors occurred within eight groups of 
histologically and biologically closely related tumour classes. We therefore defined eight 
‘methylation class families’ (MCF). Since calibrated scores represent class probabilities, it is 
possible to apply the addition rule of probabilities to sum up calibrated class scores within 
one MCF to get a class probability for the MCF.
Threshold analysis
Finding an optimal cutoff for diagnostic tests usually involves finding an optimal trade-off 
between sensitivity and specificity. If there are no preferences regarding specificity or 
sensitivity, the optimal cutoff is chosen by the upper left corner of the ROC curve or by 
maximizing the Youden index (specificity+sensitivty-1). In an application like the one 
described here, where the cost of false negative is that a tumour cannot be classified and the 
cost of a false positive is a falsely predicted methylation class, a threshold with high 
specificity is preferred. ROC analysis is typically defined for binary classification problems. 
Finding a threshold for multiclass classifiers either involves performing a ROC analysis for 
each class resulting in class-wise individual thresholds or finding some common threshold 
for all classes.
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The calibrated MC/MCF scores (here referring to MCF and MC classes that are not assigned 
to a MCF) are already validated probability estimates for the methylation class with a direct 
interpretation, i.e. we expect among all samples with scores of approx. 0.9 that 10% are 
falsely predicted. Applying an additional threshold is not required from a statistical point of 
view, but desired in clinical practice. In addition, due to calibration, scores are comparable 
across classes and it is thus reasonable to define a common threshold for all classes instead 
of finding optimal cutoff for each individual methylation class.
To determine a common threshold for the calibrated MC/MCF scores, we performed a ROC 
analysis of the maximum calibrated MC/MCF scores calculated via cross-validation. For this 
ROC analysis we defined a new binary class, i.e. samples correctly classified during the CV 
using the maximum calibrated MC/MCF score for classification were considered as 
‘classifiable’ and samples falsely classified by using this score were considered ‘non-
classifiable’.
Following this ROC analysis approach, we determined a cutoff of 0.836 that maximises the 
Youden index with a specificity of 93.8% and sensitivity of 93.4% (Extended Data 5d and 
e). A maximum specificity of 100% with a sensitivity of 82.7% can be achieved with a 
threshold of 0.958. Bootstrapped 95% confidence intervals (grey area in Extended Data 
Figure 5d) demonstrate the uncertainty of sensitivity and specificity estimates, especially in 
the left upper corner of the ROC figure, where the considered thresholds are located.
Both thresholds have been determined by cross-validation on our training data of high 
quality, but real life diagnostic samples were found to achieve slightly lower scores, due to a 
number of factors we cannot control, such as lower overall sample quality and lower tumour 
purity compared to samples in our reference cohort. Therefore, we decided to lower the 
maximum specificity threshold to allow a wider spectrum of samples to become a match. 
For this, we chose a threshold of ≥0.9 that lies in the middle between the Youden index and 
the threshold for maximum specificity.
Comparison to TCGA pan-glioma methylation classes
To compare our methylation-based classification of CNS tumours with described 
methylation classes of brain tumours by the Cancer Genome Atlas (TCGA) project, we 
downloaded the pre-processed methylation dataset described in Ceccarelli et al. 201618 
including methylation data of 418 low grade glioma and 377 glioblastoma samples analysed 
by using the Illumina 450k array or 27k array platforms. To classify our samples according 
to the TCGA pan-glioma DNA methylation classification, we trained a Random Forest 
classifier on this dataset using the 1,300 CpG probe signature provided by the authors and 
using the default settings of the Random Forest algorithms implemented in the R package 
randomForest. The results of this classification for astrocytomas, oligodendrogliomas and 
glioblastomas are shown in Extended Data Figure 3d and are given on a case-by-case basis 
in Supplementary Table 2 and 4.
Estimating tumour purity from DNA methylation data
Due to the subjective nature of histological assessment of tumour purity, we additionally 
used the Ceccarelli et al. 2016 dataset18 to train a Random Forest regression (continuous 
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response variable) model to predict tumour purity50. This Random Forest was trained on the 
1,000 most important CpG probes for purity estimation selected also by a Random Forest 
(similar to the variable selection described for the Random Forest classifier). The out-of-bag 
(i.e. RF trees in which the respective sample, for which purity is predicted, was not used for 
training) mean squared error of the final model is 0.015, indicating that this model is able to 
yield reasonable predictions of tumour purity from methylation data (Extended Data Figure 
3a-c). The estimated tumour purity for individual cases is given in Supplementary Table 2 
and 4.
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Extended Data
Extended Data Figure 1 |. Unsupervised clustering of the DNA methylation-based reference 
cohort.
a, Heatmap showing the pairwise Pearson correlation (lower left) of the 32,000 most 
variably methylated CpG probes of all 2,801 biologically independent samples of the 
reference cohort. A detailed view on closely related ependymal classes (upper right) and the 
three subclasses identified in ATRT tumours (lower right) indicates higher correlation within 
classes. The colour code and abbreviations are identical to main Figure 1a. b, Barplot 
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showing eigenvalue frequencies of a principal component analysis (PCA) using the same 
32,000 most variably methylated CpG probes of all 2,801 biologically independent samples 
as in (a). The number of non-trivial components were determined by comparing eigenvalues 
to the maximum eigenvalue of a PCA using randomized beta-values (shuffling of sample 
labels per probe). c, X and Y coordinates of the first five of a total of 500 iterations of t-SNE 
dimensionality reduction generated by random downsampling to 90% of the 2,801 
biologically independent samples to assess clustering stability. Axis positions of individual 
cases are connected by a line coloured according to the colour code of Figure 1a. The 
depiction illustrates the close proximity of cases of the same class across iterations, 
indicative of a high stability independent of the exact composition of the reference cohort. d, 
Pairwise correlation of X and Y coordinates between 2,801 biologically independent 
samples over all iterations of the downsampling analysis demonstrates a very high 
correlation within classes (average correlation 0.982), indicating a high stability of the t-
SNE analysis.
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Extended Data Figure 2 |. Unsupervised clustering is not biased by a range of possible 
confounding factors.
a, t-SNE representations of the 2,801 biologically independent samples constituting the 
reference cohort as shown in Figure 1b overlaid with potentially confounding factors (b-f). 
b, Distribution of patient sex among the classes illustrates equal or near equal distribution of 
many classes, but also an expected enrichment for one sex in some classes (e.g. female in 
meningioma or CNS high-grade neuroepithelial tumour with MN1 alteration). c, Patient age 
illustrates the expected age distribution of many tumour classes. d-f, The slightly uneven 
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distribution of type of material (e.g. pilocytic astrocytoma or meningioma) (d), array 
preparation date (e), and tissue source (f) are related to the specifics of assembling the 
reference cohort and do not indicate an apparent confounding effect on the unsupervised 
clustering.
Extended Data Figure 3 |. Estimation of tumour purity and relation to TCGA pan-glioma 
methylation classes.
a, A Random Forest model was trained to predict ABSOLUTE tumour purity estimates50 
using the TCGA pan-glioma dataset (795 biologically independent samples)18. The plot 
Capper et al. Page 17
Nature. Author manuscript; available in PMC 2018 September 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
shows ABSOLUTE purity estimates and out-of-bag Random Forest tumour purity 
predictions (i.e. using only RF trees for which the respective sample was not involved in the 
training). The estimated mean squared error is 0.015, indicating that this model is able to 
yield reasonable predictions of tumour purity from methylation data. b, Bar plot showing the 
distribution of Random Forest predicted purity in the reference dataset (2,801 biologically 
independent samples). Purity estimates have been transformed into five categories indicated 
by different shades of blue. The exact case-by-case values are given in Supplementary Table 
2. The median estimated purity in the reference cohort is 66% (range 42% to 87%) and 78% 
of samples have an estimated purity of at least 60%. c, t-SNE representation of the reference 
cohort (2,801 biologically independent samples) overlayed with Random Forest predicted 
purity categories. Methylation classes are generally composed of mixed tumour purity 
categories. Tumour purity shows some association with the WHO grade (WHO I median 
tumour purity 60%, range 39–77%; WHO II median 66%, range 43–80%; WHO III median 
68% range 54–84%; WHO IV median 69% range 49–87%). A further association of tumour 
purity with the composition of classes in the unsupervised t-SNE analysis was not evident. 
d, t-SNE representation of the reference cohort (2,801 biologically independent samples) 
overlayed with predicted TCGA pan-glioma DNA methylation classes according to 
Ceccarelli et al. 2016. Pan-glioma methylation classes were predicted by training a Random 
Forest (RF) on the Ceccarelli et al. 2016 dataset including methylation data of 418 low grade 
glioma and 377 glioblastoma samples acquired using the Illumina 450k and 27k platforms. 
The RF was trained using the 1,300 CpG signature as described by the authors18 and using 
the default settings of the RF algorithm implemented in the R package randomForest. Pan-
glioma class prediction was only performed for subsets of mostly adult astrocytomas, 
oligodendrogliomas and glioblastomas (magnified areas) included in the Ceccarelli et al. 
2016 data set. LGm1, LGm2 and LGm3 show a high overlap with the methylation classes A 
IDH HG, A IDH and O IDH, respectively. LGm4 shows highest overlap with methylation 
class GBM RTK II. LGm5 shows highest overlap with methylation classes GBM MES and 
GBM RTK I. LGm6 show highest overlap with DMG K27, GBM MID and GBM MYCN.
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Extended Data Figure 4 |. Development of the Random Forest classifier.
a, The RF training consists of four steps. First, a basic filtering for probes that are not 
included on the EPIC array, probes located on the X and Y- chromosomes, probes affected 
by SNPs, and probes not mapping uniquely to the genome is performed. In a second step, 
the probe-wise batch effects between samples from FFPE and frozen material are estimated 
and adjusted by a linear model approach. In a third step, feature selection is performed by 
training a RF using all probes and selecting the 10,000 probes with highest variable 
importance measure. In a last step, the final RF is trained using only the 10,000 selected 
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probes. The validation of the RF classifier involves a three-fold nested cross-validation 
(CV). In the outer loop of the CV the complete RF training procedure described before is 
applied to the training data and the resulting RF is used to predict the test data to generate 
RF scores. In the inner loop of the CV a three-fold CV is applied to training data of the outer 
loop in order to generate RF scores independent of the test data in the outer loop. These 
scores are then used to fit a calibration model, i.e. a L2-penalized, multinomial, logistic 
regression that takes the RF scores of the test data in the outer CV loop to estimate tumour 
class probabilities (P1, P2, P3). To fit a calibration model to estimate class probabilities of 
diagnostic samples using all data in the reference set, the RF scores generated in the outer 
CV loop are used. b, Schematic depiction of three exemplary binary decision trees of the 
Random Forest classifier (left), and magnification on five exemplary decisions nodes 
relevant for glioblastoma classification (right). For prediction, a diagnostic sample enters the 
root node of each of the 10,000 trees. At every decision node, the decision path is 
determined on the methylation level of a single CpG, until reaching a terminal node that 
provides the class prediction. The joint class prediction of all trees represents the raw 
prediction score. The colour code and abbreviations are identical to Figure 1a.
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Extended Data Figure 5 |. Comparison of raw and calibrated classifier scores and threshold 
definition.
a, Density plots illustrating the distribution of raw and calibrated classifier scores for 
samples correctly classified during cross-validation (n=2,701 independent biological 
samples for raw and n=2769 independent biological samples for calibrated), depicted for 
each methylation class or methylation class family (MCF). Score calibration results in a 
harmonization of score distribution and allows the establishment of a shared classification 
threshold. Three thresholds for maximizing specificity (0.958), maximizing the Youden 
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index (0.836), and the cutoff used in this study (0.9) are indicated by red lines (see also 
panels d and e). b, Multivariate score calibration exemplified in a ternary plot showing 
scores of the three ATRT subclasses (MYC, SHH, and TYR; together n=112 independent 
biological samples). Arrows indicate transformation of the scores for individual samples by 
the calibration model, which increases the discrimination between the three subclasses. c, 
The accuracy of prediction of the Random Forest classifier constructed of n=2801 
biologically independent samples (measured by misclassification error, area under receiver 
operating characteristic curve (AUC), Brier score, multiclass Sensitivity and Specificity) is 
improved by score calibration and by combining classes into methylation class families 
(MCF). d, To determine a common threshold for the calibrated MCF scores, we performed a 
Receiver Operating Characteristic (ROC) analysis of the maximum calibrated MCF scores 
of all n=2801 biologically independent samples calculated via cross-validation. For this 
ROC analysis we defined a new binary class, i.e. samples correctly classified during the CV 
using the maximum calibrated MCF score for classification were considered as ‘classifiable’ 
(n=2769) and samples that got falsely classified by using this score were considered ‘non 
classifiable’ (n=32). Three thresholds for different sensitivity and specificity are highlighted 
in the ROC curve: A threshold of 0.958 achieving a maximum specificity of 1 with a 
sensitivity of 0.827, a threshold of 0.836 obtaining a maximum Youden index with 
Specificity 0.938 and sensitivity 0.934, and our recommended compromise threshold of 0.9 
that results in a specificity of 0.938 and a sensitivity of 0.9. Bootstrapped 95% confidence 
intervals for estimated sensitivity and specificity are indicated in grey. e, Sensitivity and 
specificity for all possible thresholds applied to cross-validated maximum MCF classifier 
scores of all n=2801 biologically independent samples. Three thresholds for maximizing 
specificity (0.958), maximizing the Youden index (0.836) and 0.9 are highlighted by red 
lines.
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Extended Data Figure 6 |. Diagnostic utility of the DNA-methylation based classifier, assessed at 
different centres.
a, Implementation of the DNA methylation classifier by five external centres. In total, 401 
independent biological samples were analysed. 78% matched to an established class with a 
cut-off score of ≥0.9 (class colours as in Figure 1a). A new diagnosis was established in 12% 
of cases. b, Depiction of individual centre results, illustrating the different composition of 
samples included in the analysis, variation in the rate of non-matching cases, and of cases 
where a new diagnosis was established. Case-by-case details are given in Supplementary 
Table 6.
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Extended Data Figure 7 |. Inter-centre and inter-platform reproducibility of DNA methylation-
based classification.
a, Calibrated scores of 53 independent biological samples representing diagnostic CNS 
tumour cases analysed at the University of Heidelberg and at the New York University 
pathology department. Both laboratories performed independent DNA extraction, array 
hybridization, and data analysis. Cases falling into green areas were classified identically in 
both centres (96%); cases in the red area were non-classifiable in one centre (4%). None of 
the 53 samples was assigned to a different methylation class by the two centres. b, Copy-
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number profiles calculated from the array data generated at both centres were highly 
comparable and allowed identification of chromosomal gains, losses, amplifications, and 
deletions. Calculations and interpretation were performed once at each centre. c, Plot of 
maximum raw classification scores of 16 different tumour samples generated using both 
450k and EPIC arrays. All cases fall close to the bisecting line (red) indicating a high 
concordance of the scores. Further, the methylation class prediction was identical for all 
samples. d, The CNS tumour classifier also performs well with data generated by whole-
genome bisulfite sequencing (WGBS). The plot shows classifier scores calculated from 
WGBS and 450k arrays of 50 cases comprising 11 different brain tumour entities (bisecting 
line in red). Methylation beta-values were calculated from high-coverage WGBS data (>10 
fold average coverage) and run through the CNS tumour classifier and plotted against the 
same case analysed using 450k arrays. The highest class prediction score was identical in all 
cases.
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Extended Data Figure 8 |. 
Sample website PDF report of a IDH wildtype glioblastoma sample.
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Extended Data Figure 9 |. 
Exemplary workflow and timeline of diagnostic methylation profiling.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Authors 
David Capper#1,2,3,4, David T.W. Jones#5,6, Martin Sill#5,6,7, Volker Hovestadt#8,+, 
Daniel Schrimpf1,2, Dominik Sturm5,6,9, Christian Koelsche1,2, Felix Sahm1,2, Lukas 
Chavez5,6, David E. Reuss1,2, Annekathrin Kratz1,2, Annika K. Wefers1,2, Kristin 
Huang1,2, Kristian W. Pajtler5,6,9, Leonille Schweizer1,3, Damian Stichel1,2, Adriana 
Olar10, Nils W. Engel11,12, Kerstin Lindenberg2, Patrick N. Harter13, Anne 
Braczynski13, Karl H. Plate13, Hildegard Dohmen14, Boyan K. Garvalov14, Roland 
Coras15, Annett Hölsken15, Ekkehard Hewer16, Melanie Bewerunge-Hudler17, 
Matthias Schick17, Roger Fischer17, Rudi Beschorner18, Jens Schittenhelm18, Ori 
Staszewski19, Khalida Wani20, Pascale Varlet21, Melanie Pages21, Petra 
Temming22, Dietmar Lohmann23, Florian Selt5,9,24, Hendrik Witt5,6,9, Till 
Milde5,8,9,24, Olaf Witt5,8,9,24, Eleonora Aronica25, Felice Giangaspero26, Elisabeth 
Rushing27, Wolfram Scheurlen28, Christoph Geisenberger29,30, Fausto J. 
Capper et al. Page 27
Nature. Author manuscript; available in PMC 2018 September 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Rodriguez31, Albert Becker32, Matthias Preusser33, Christine Haberler34, Rolf 
Bjerkvig35,36, Jane Cryan37, Michael Farrell37, Martina Deckert38, Jürgen Hench39, 
Stephan Frank39, Jonathan Serrano40, Kasthuri Kannan40, Aristotelis Tsirigos40, 
Wolfgang Brück41, Silvia Hofer42, Stefanie Brehmer43, Marcel Seiz-Rosenhagen43, 
Daniel Hänggi43, Volkmar Hans44,45, Stephanie Rozsnoki46, Jordan R. Hansford47, 
Patricia Kohlhof48, Bjarne W. Kristensen49, Matt Lechner50, Beatriz Lopes51, 
Christian Mawrin52, Ralf Ketter53, Andreas Kulozik5,9, Ziad Khatib54, Frank 
Heppner3,55, Arend Koch3, Anne Jouvet56, Catherine Keohane57, Helmut 
Mühleisen58, Wolf Mueller59, Ute Pohl60, Marco Prinz19,61, Axel Benner7, Marc 
Zapatka8, Nicholas G. Gottardo62,63,64, Pablo Hernáiz Driever65, Christof M. 
Kramm66, Hermann L. Müller67, Stefan Rutkowski68, Katja von Hoff65,68, Michael C. 
Frühwald69, Astrid Gnekow69, Gudrun Fleischhack22, Stephan Tippelt22, Gabriele 
Calaminus70, Camelia-Maria Monoranu71, Arie Perry72, Chris Jones73, Thomas S. 
Jacques74, Bernhard Radlwimmer8, Marco Gessi32, Torsten Pietsch32, Johannes 
Schramm75, Gabriele Schackert76, Manfred Westphal77, Guido Reifenberger78, 
Pieter Wesseling79, Michael Weller80, Vincent Peter Collins81, Ingmar Blümcke15, 
Martin Bendszus82, Jürgen Debus83, Annie Huang84, Nada Jabado85, Paul A. 
Northcott86, Werner Paulus46, Amar Gajjar87, Giles Robinson87, Michael D. 
Taylor88, Zane Jaunmuktane89,90, Marina Ryzhova91, Michael Platten92, Andreas 
Unterberg29, Wolfgang Wick93, Matthias A. Karajannis94, Michel Mittelbronn13,95, 
Till Acker14, Christian Hartmann96, Kenneth Aldape97, Ulrich Schüller12,98,99, Rolf 
Buslei15,100, Peter Lichter8, Marcel Kool5,6, Christel Herold-Mende29, David W. 
Ellison101, Martin Hasselblatt46, Matija Snuderl102, Sebastian Brandner89, Andrey 
Korshunov1,2, Andreas von Deimling1,2,#, and Stefan M. Pfister5,6,9,#
Affiliations
1Department of Neuropathology, University Hospital Heidelberg, Heidelberg, 
Germany 2Clinical Cooperation Unit Neuropathology, German Cancer Consortium 
(DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany 3Charité 
– Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, 
Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of 
Neuropathology 4German Cancer Consortium (DKTK), Partner Site Berlin, German 
Cancer Research Center (DKFZ) Heidelberg, Germany 5Hopp Children´s Cancer 
Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany 6Division of Pediatric 
Neurooncology, German Cancer Consortium (DKTK), German Cancer Research 
Center (DKFZ), Heidelberg, Germany 7Division of Biostatistics, German Cancer 
Research Center (DKFZ), Heidelberg, Germany 8Division of Molecular Genetics, 
German Cancer Research Center (DKFZ), Heidelberg, Germany 9Department of 
Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, 
Heidelberg, Germany 10Departments of Pathology and Laboratory Medicine & 
Neurosurgery, Medical University of South Carolina, Hollings Cancer Center, 
Charleston, SC, 29425, USA 11Department of Oncology and Hematology with 
Sections Bone Marrow Transplant and Pneumology, Hubertus Wald Tumorzentrum / 
University Cancer Center Hamburg, University Medical Center Hamburg, Hamburg, 
Germany 12Center for Neuropathology and Prion Research, Ludwig-Maximilians-
Capper et al. Page 28
Nature. Author manuscript; available in PMC 2018 September 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
University, Munich, Germany 13Institute of Neurology (Edinger Institute), Goethe-
University Frankfurt and German Cancer Consortium (DKTK), Partner Site 
Frankfurt/Mainz, Frankfurt am Main, German Cancer Research Center (DKFZ) 
Heidelberg, Germany 14Institute of Neuropathology, University of Giessen, Giessen, 
Germany 15Neuropathological Institute, University Hospitals Erlangen, Friedrich 
Alexander University Erlangen-Nuremberg, Germany 16Institute of Pathology, 
University of Bern, Bern, Switzerland 17Genomics and Proteomics Core Facility, 
German Cancer Research Center (DKFZ), Heidelberg, Germany 18Institute of 
Pathology and Neuropathology, Department of Neuropathology, University Hospital 
Tübingen, Tübingen, Germany 19Institute of Neuropathology, Medical Center – 
University of Freiburg, Faculty of Medicine, University of Freiburg, Germany 
20Department of Translational Molecular Pathology, University of Texas MD 
Anderson Cancer Center, Houston, TX 77030, USA 21Department of 
Neuropathology, Centre Hospitalier Sainte Anne, Paris, France 22Pediatrics III, 
Pediatric Oncology and Hematology, University Hospital Essen, Essen, Germany 
23Eye Cancer Research Group, Faculty of Medicine, University of Duisburg-Essen, 
Essen, Germany 24CCU Pediatric Oncology (G340) German Cancer Research 
Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany 
25Department of (Neuro)Pathology, Academic Medisch Centrum (AMC) and 
Swammerdam Institute for Life Sciences, Center for Neuroscience, University of 
Amsterdam; Stichting Epilepsie Instellingen Nederland (SEIN), The Netherlands 
26Department of Radiological, Oncological and Anatomo-Pathological Sciences, 
Sapienza University, Rome, Italy and IRCCS Neuromed, Pozzilli (Is), Italy 
27Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland 
28Cnopf’sche Kinderklinik Nuremberg, Nuremberg, Germany 29Department of 
Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany 30Hubrecht 
Institute-KNAW (Royal Netherlands Academy of Arts and Sciences), Uppsalalaan 8, 
3584 CT Utrecht, Netherlands 31Division of Neuropathology of the Johns Hopkins 
University School of Medicine, Baltimore, MD, USA 32Department of 
Neuropathology, University of Bonn, Bonn, Germany 33Department of Medicine I, 
Comprehensive Cancer Center Vienna, CNS Unit (CCC-CNS), Medical University of 
Vienna, Vienna, Austria 34Institute of Neurology, Medical University of Vienna, 
Vienna, Austria 35Department of Biomedicine, University of Bergen, Bergen, Norway 
36NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg 
Institute of Health, Luxembourg. 37Department of Neuropathology, Beaumont 
Hospital, Dublin, Ireland 38Department of Neuropathology, University Hospital of 
Cologne, Cologne, Germany 39Department of Neuropathology, Institute of 
Pathology, Basel University Hospital, Basel, Switzerland 40NYU Langone Medical 
Center, New York, NY, USA 41Institute of Neuropathology, University Medical Center 
Göttingen, Göttingen, Germany 42Division of Oncology, Luzerner Kantonsspital, 
Luzern, Switzerland 43Department of Neurosurgery, University Medical Center 
Mannheim, University of Heidelberg 44Institut für Neuropathologie, Evangelisches 
Krankenhaus Bielefeld gGmbH, Bielefeld, Germany 45Institut für Neuropathologie, 
Universitätskinikum Essen, Essen, Germany 46Institute of Neuropathology, 
Capper et al. Page 29
Nature. Author manuscript; available in PMC 2018 September 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
University Hospital Münster, Münster, Germany 47Children’s Cancer Centre, Royal 
Children’s Hospital; Murdoch Children’s Research Institute; Department of 
Pediatrics, University of Melbourne; Melbourne, Australia 48Institute for Pathology, 
Katharinenhospital Stuttgart, Stuttgart, Germany 49Department of Pathology, 
Odense University Hospital, Department of Clinical Research, University of 
Southern Denmark, Odense, Denmark 50University College London Cancer Institute 
and University College London Hospitals, London, United Kingdom. 51Department 
of Pathology, University of Virginia, Charlottesville, Virginia, USA 52Institute of 
Neuropathology, Otto-von-Guericke-University, Magdeburg 53Department of 
Neurosurgery, University Hospital Saarland, Homburg, Saar, Germany 54Nicklaus 
Children’s Hospital Brain Institute, Miami, FL, 33155, USA 55Cluster of Excellence, 
NeuroCure, and Berlin Institute of Health (BIH), Berlin, Germany 56Département de 
Pathologie et Neuropathologie, Hôpital Neurologique, Hospices Civils de Lyon, 
Lyon, France 57Department of Neuropathology, Cork University Hospital, Cork, 
Ireland 58Department of Pathology, Ludwigsburg Hospital, Ludwigsburg, Germany 
59Department of Neuropathology, Leipzig University, Leipzig, Germany 
60Department of Cellular Pathology, Queen’s Hospital, Romford, UK 61BIOSS 
Centre for Biological Signalling Studies, University of Freiburg, Germany 
62Department of Pediatric Oncology and Haematology, Princess Margaret Hospital 
for Children, GPO Box D184, Perth, Western Australia 6840, Australia 63Telethon 
Kids Institute, University of Western Australia, PO Box 855, Perth, Western Australia 
6872, Australia 64School of Paediatrics and Child Health, University of Western 
Australia, GPO Box D184, Perth, Western Australia 6840, Australia 65Department of 
Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, 
Germany 66Division of Pediatric Hematology and Oncology, University Medical 
Center Goettingen, Goettingen, Germany 67Department of Pediatrics and Pediatric 
Hematology / Oncology, Klinikum Oldenburg AöR, Medical Campus University 
Oldenburg, 26133 Oldenburg, Germany 68Department for Pediatric Hematology and 
Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany 69Children’s 
Hospital Augsburg, Swabian Children’s Cancer Centre, Augsburg, Germany 
70Department of Pediatric Hematology/Oncology, University of Bonn Medical Center, 
Bonn, Germany 71Department of Neuropathology, Insitute of Pathology, 
Comprehensive Cancer Center (CCC) Mainfranken, University of Würzburg, 
Würzburg, Germany 72Department of Pathology, University of California San 
Francisco, San Francisco, CA, USA 73Division of Molecular Pathology, Institute of 
Cancer Research, London, UK 74Developmental Biology and Cancer Programme, 
UCL Great Ormond Street Institute of Child Health and Histopathology Department, 
Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK 
75Medical Faculty, University of Bonn Medical School, Bonn, Germany 76Department 
of Neurosurgery, University Hospital Carl Gustav Carus, Technische Universität 
Dresden, Dresden, Germany. 77Department of Neurosurgery, University Hospital 
Hamburg-Eppendorf, Hamburg, Germany. 78Department of Neuropathology, 
Heinrich Heine University Düsseldorf and German Cancer Consortium (DKTK), 
partner site Essen/Düsseldorf, German Cancer Research Center (DKFZ) 
Capper et al. Page 30
Nature. Author manuscript; available in PMC 2018 September 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Heidelberg, Germany 79Department of Pathology, Princess Máxima Center for 
Pediatric Oncology and University Medical Center Utrecht, Utrecht, the Netherlands, 
and Department of Pathology, VU University Medical Center, Amsterdam, the 
Netherlands 80Department of Neurology, University Hospital and University of 
Zurich, Zurich, Switzerland 81Department of Pathology, Division of Molecular 
Histopathology, University of Cambridge, Cambridge, UK. 82Department of 
Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany 83Department 
of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany 
84Department of Pediatrics, Laboratory Medicine and Pathobiology, University of 
Toronto, Toronto, Ontario, Canada 85Division of Hematology/Oncology, McGill 
University, Montreal, QC, Canada 86Department of Developmental Neurobiology, St. 
Jude Children’s Research Hospital, Memphis, TN, USA 87Department of Oncology, 
St. Jude Children’s Research Hospital, Memphis, TN, USA 88Division of 
Neurosurgery, Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital for 
Sick Children, University of Toronto, Toronto, Canada 89Division of 
Neuropathology,UCL Hospitlals and Department of Neurodegeneration, Institute of 
Neurology, University College London, Queen Square, WC1N 3BG, London, UK 
90Division of Neuropathology, UCL Hospitals and Department of Molecular 
Neuroscience, Institute of Neurology, University College London, Queen Square, 
WC1N 3BG, London 91NN Burdenko Neurosurgical Institute, Moscow, Russia 
92Department of Neurology, Universitätsmedizin Mannheim, Medical Faculty 
Mannheim, Heidelberg University, Mannheim, Germany 93Department of Neurology, 
Heidelberg University Hospital, Heidelberg, Germany 94Department of Pediatrics, 
Memorial Sloan Kettering Cancer Center, New York, NY, USA 95NORLUX Neuro-
Oncology Laboratory, Luxembourg Institute of Health (LIH); Luxembourg Centre for 
Systems Biomedicine (LCSB), University of Luxembourg; Laboratoire national de 
santé (LNS), Dudelange; Luxembourg Centre of Neuropathology (LCNP), all 
Luxembourg. 96Department of Neuropathology, Hannover Medical School (MHH), 
Hannover, Germany 97Department of Pathology, University of Toronto, Toronto, 
Ontario, Canada 98Institute of Neuropathology and Department of Pediatric 
Hematology and Oncology, University Medical Center, Hamburg-Eppendorf, 
Germany 99Research Institute Children’s Cancer Center, Hamburg, Germany 
100Section Neuropathology, Institute of Pathology, Sozialstiftung Bamberg, Klinikum 
am Bruderwald, Bamberg, Germany 101Department of Pathology, St. Jude 
Children’s Research Hospital, Memphis, TN, USA 102Division of Neuropathology, 
Department of Pathology, NYU Langone Medical Center, New York, NY, USA
Acknowledgments
We thank U. Lass, A. Habel, I Oezen for technical and administrative support, the Microarray unit of the Genomics 
and Proteomics Core Facility (DKFZ) for methylation services, the German Glioma Network and the 
Neuroonkologische Arbeitsgemeinschaft for data sharing. This research was supported by the DKFZ-Heidelberg 
Center for Personalized Oncology (DKFZ-HIPO_036), the German Childhood Cancer Foundation (DKS 2015.01), 
an Illumina Medical Research Grant, the DKTK joint funding project ‘Next Generation Molecular Diagnostics of 
Malignant Gliomas’, the A Kids’ Brain Tumour Cure (PLGA) Foundation, the Brain Tumour Charity (UK) for the 
Everest Centre for Paediatric Low-Grade Brain Tumour Research, the Friedberg Charitable Foundation and the 
Sohn Conference Foundation (to M. Snuderl and M. Karajannis), the RKA-Förderpool (Project 37) and Stichting 
Capper et al. Page 31
Nature. Author manuscript; available in PMC 2018 September 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Kinderen Kankervrij and Stichting AMC Foundation (to E. Aronica), NIH/NCI 5T32CA163185 (to A. Olar), 
NIH/NCI Cancer Center Support Grant P30 CA008748 to MSKCC, the Luxembourg National Research Fond (FNR 
PEARL P16/BM/11192868 to M. Mittelbronn) and the National Institute of Health Research (NIHR) UCLH/UCL 
Biomedical Research Centre (S. Brandner).
References
1. Louis DN , Ohgaki H , Wiestler OD & Cavenee WK WHO Classification of Tumours of the Central 
Nervous System (revised 4th edition). (IARC, 2016).
2. van den Bent MJ Interobserver variation of the histopathological diagnosis in clinical trials on 
glioma: a clinician’s perspective. Acta Neuropathol. 120, 297–304, doi:10.1007/s00401-010-0725-7 
(2010). [PubMed: 20644945] 
3. Ellison DW et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical 
relevance in European trial cohorts. J Negat Results Biomed 10, 7, doi:10.1186/1477-5751-10-7 
(2011). [PubMed: 21627842] 
4. Sturm D et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. 
Cell 164, 1060–1072, doi:10.1016/j.cell.2016.01.015 (2016). [PubMed: 26919435] 
5. Fernandez AF et al. A DNA methylation fingerprint of 1628 human samples. Genome Res. 22, 407–
419, doi:10.1101/gr.119867.110 (2012). [PubMed: 21613409] 
6. Hovestadt V et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation 
sequencing. Nature 510, 537–541, doi:10.1038/nature13268 (2014). [PubMed: 24847876] 
7. Moran S et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, 
retrospective analysis. Lancet Oncol. 17, 1386–1395, doi:10.1016/S1470-2045(16)30297-2 (2016). 
[PubMed: 27575023] 
8. Hovestadt V et al. Robust molecular subgrouping and copy-number profiling of medulloblastoma 
from small amounts of archival tumour material using high-density DNA methylation arrays. Acta 
Neuropathol. 125, 913–916, doi:10.1007/s00401-013-1126-5 (2013). [PubMed: 23670100] 
9. Sturm D et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological 
subgroups of glioblastoma. Cancer Cell 22, 425–437, doi:10.1016/j.ccr.2012.08.024 (2012). 
[PubMed: 23079654] 
10. Reuss DE et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other 
tumor entities. Acta Neuropathol. 130, 407–417, doi:10.1007/s00401-015-1454-8 (2015). 
[PubMed: 26087904] 
11. Pajtler KW et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, 
Histopathological Grades, and Age Groups. Cancer Cell 27, 728–743, doi:10.1016/j.ccell.
2015.04.002 (2015). [PubMed: 25965575] 
12. Lambert SR et al. Differential expression and methylation of brain developmental genes define 
location-specific subsets of pilocytic astrocytoma. Acta Neuropathol. 126, 291–301, doi:10.1007/
s00401-013-1124-7 (2013). [PubMed: 23660940] 
13. Thomas C et al. Methylation profiling of choroid plexus tumors reveals 3 clinically distinct 
subgroups. Neuro Oncol. 18, 790–796, doi:10.1093/neuonc/nov322 (2016). [PubMed: 26826203] 
14. Mack SC et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. 
Nature 506, 445–450, doi:10.1038/nature13108 (2014). [PubMed: 24553142] 
15. Johann PD et al. Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic 
Subgroups with Distinct Enhancer Landscapes. Cancer Cell 29, 379–393, doi:10.1016/j.ccell.
2016.02.001 (2016). [PubMed: 26923874] 
16. Wiestler B et al. Integrated DNA methylation and copy-number profiling identify three clinically 
and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 128, 561–571, doi:
10.1007/s00401-014-1315-x (2014). [PubMed: 25008768] 
17. van der Maaten L & Hinton G Visualizing data using t-SNE. The Journal of Machine Learning 
Research 9, 85 (2008).
18. Ceccarelli M et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of 
Progression in Diffuse Glioma. Cell 164, 550–563, doi:10.1016/j.cell.2015.12.028 (2016). 
[PubMed: 26824661] 
Capper et al. Page 32
Nature. Author manuscript; available in PMC 2018 September 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
19. Breiman L Random forests. Machine learning 45, 5–32 (2001).
20. Sokolova M & Lapalme G A systematic analysis of performance measures for classification tasks. 
Inf. Process. Manage. 45, 427–437, doi:10.1016/j.ipm.2009.03.002 (2009).
21. Sahm F et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated 
diagnosis and identifies actionable targets. Acta Neuropathol. 131, 903–910, doi:10.1007/
s00401-015-1519-8 (2016). [PubMed: 26671409] 
22. Weller M et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using 
genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient 
groups. Acta Neuropathol. 129, 679–693, doi:10.1007/s00401-015-1409-0 (2015). [PubMed: 
25783747] 
23. Cancer Genome Atlas Research, N. et al. Comprehensive, Integrative Genomic Analysis of Diffuse 
Lower-Grade Gliomas. N. Engl. J. Med. 372, 2481–2498, doi:10.1056/NEJMoa1402121 (2015). 
[PubMed: 26061751] 
24. conumee: Enhanced copy-number variation analysis using Illumina 450k methylation arrays. R 
package version 0.99.4, http://www.bioconductor.org/packages/release/bioc/html/conumee.html. v. 
1.4.2 (2015).
25. Bady P , Delorenzi M & Hegi ME Sensitivity Analysis of the MGMT-STP27 Model and Impact of 
Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other 
Tumors. J. Mol. Diagn. 18, 350–361, doi:10.1016/j.jmoldx.2015.11.009 (2016). [PubMed: 
26927331] 
Online Only References
26. Korshunov A et al. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are 
molecularly similar and comprise a single nosologic entity. Acta Neuropathol. 131, 137–146, doi:
10.1007/s00401-015-1493-1 (2016). [PubMed: 26482474] 
27. Korshunov A et al. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), 
ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single 
clinicopathological entity. Acta Neuropathol. 128, 279–289, doi:10.1007/s00401-013-1228-0 
(2014). [PubMed: 24337497] 
28. Holsken A et al. Adamantinomatous and papillary craniopharyngiomas are characterized by 
distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun 
4, 20, doi:10.1186/s40478-016-0287-6 (2016). [PubMed: 26927026] 
29. Heim S et al. Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. Brain Pathol. 26, 
199–205, doi:10.1111/bpa.12282 (2016). [PubMed: 26113311] 
30. Koelsche C et al. Melanotic tumors of the nervous system are characterized by distinct mutational, 
chromosomal and epigenomic profiles. Brain Pathol. 25, 202–208, doi:10.1111/bpa.12228 (2015). 
[PubMed: 25399693] 
31. Jones DT et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. 
Genet. 45, 927–932, doi:10.1038/ng.2682 (2013). [PubMed: 23817572] 
32. Jones DT et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 488, 100–
105, doi:10.1038/nature11284 (2012). [PubMed: 22832583] 
33. Pietsch T et al. Prognostic significance of clinical, histopathological, and molecular characteristics 
of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta 
Neuropathol. 128, 137–149, doi:10.1007/s00401-014-1276-0 (2014). [PubMed: 24791927] 
34. R: A language and environment for statistical computing. (R Foundation for Statistical Computing, 
Vienna, Austria, 2016).
35. Huber W et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods 
12, 115–121, doi:10.1038/nmeth.3252 (2015). [PubMed: 25633503] 
36. Aryee MJ et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of 
Infinium DNA methylation microarrays. Bioinformatics 30, 1363–1369, doi:10.1093/
bioinformatics/btu049 (2014). [PubMed: 24478339] 
Capper et al. Page 33
Nature. Author manuscript; available in PMC 2018 September 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
37. Leek JT & Storey JD Capturing heterogeneity in gene expression studies by surrogate variable 
analysis. PLoS genetics 3, 1724–1735, doi:10.1371/journal.pgen.0030161 (2007). [PubMed: 
17907809] 
38. Leek JT & Storey JD A general framework for multiple testing dependence. Proc. Natl. Acad. Sci. 
U. S. A. 105, 18718–18723, doi:10.1073/pnas.0808709105 (2008). [PubMed: 19033188] 
39. Breiman L Classification and regression trees. (Chapman & Hall/CRC, 1984).
40. Liaw A & Wiener M Classification and Regression by randomForest. R News 2, 18–22 (2002).
41. Chen C , Liaw A & Breiman L Using random forest to learn imbalanced data. University of 
California, Berkeley, 1–12 (2004).
42. Kim KI & Simon R Overfitting, generalization, and MSE in class probability estimation with high-
dimensional data. Biom J 56, 256–269, doi:10.1002/bimj.201300083 (2014). [PubMed: 24338793] 
43. Boström H in Machine Learning and Applications, 2008. ICMLA’08. Seventh International 
Conference on. 121–126 (IEEE).
44. Smola AJ Advances in large margin classifiers. (MIT press, 2000).
45. Friedman J , Hastie T & Tibshirani R Regularization paths for generalized linear models via 
coordinate descent. Journal of statistical software 33, 1 (2010). [PubMed: 20808728] 
46. Appel IJ , Gronwald W & Spang R Estimating classification probabilities in high-dimensional 
diagnostic studies. Bioinformatics 27, 2563–2570 (2011). [PubMed: 21784795] 
47. Hand DJ & Till RJ A simple generalisation of the area under the ROC curve for multiple class 
classification problems. Machine learning 45, 171–186 (2001).
48. Simon R Class probability estimation for medical studies. Biom J 56, 597–600, doi:10.1002/bimj.
201300296 (2014). [PubMed: 24615788] 
49. Brier GW Verification of forecasts expressed in terms of probability. Monthly Weather Review 78, 
1–3, doi:10.1175/1520-0493(1950)078<0001:vofeit>2.0.co;2 (1950).
50. Carter SL et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. 
Biotechnol. 30, 41 3-421, doi:10.1038/nbt.2203 (2012). [PubMed: 22231093] 
Capper et al. Page 34
Nature. Author manuscript; available in PMC 2018 September 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1 |. Establishing of the DNA methylation-based CNS tumour reference cohort.
a, Overview of the 82 CNS tumour methylation classes and nine control tissue methylation 
classes of the reference cohort. The methylation classes are grouped by histology and color-
coded. Category 1 methylation classes are equivalent to a WHO entity, category 2 
methylation classes are a subgroup of a WHO entity, category 3 methylation classes are not 
equivalent to a unique WHO entity with combining of WHO grades, category 4 methylation 
classes are not equivalent to a unique WHO entity with combining of WHO entities, and 
category 5 methylation classes are not recognized as a WHO entity. Full names and further 
details of the abbreviated 91 classes are given in Supplementary Table 1. Embryonal 
tumours: shades of blue; Glioblastomas: shades of green; Other gliomas: shades of violet; 
Ependymomas: shades of red; Glio-neuronal tumours: shades of orange; IDH-mutated 
gliomas: shades of yellow; Choroid plexus tumours: shades of brown; Pineal region 
tumours: shades of mint green; Melanocytic tumours: shades of dark blue; Sellar region 
tumours: shades of cyan; Mesenchymal tumours: shades of pink; Nerve tumours: shades of 
beige; Haematopoietic tumours: shades of dark purple; Control tissues: shades of grey. b, 
Unsupervised clustering of reference cohort samples (n=2,801) using t-SNE dimensionality 
reduction. Individual samples are colour-coded in the respective class colour (n=91) and 
labelled with the class abbreviation. The colour code and abbreviations are identical to 
Figure 1a.
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Figure 2 |. Development and cross-validation of the DNA methylation-based CNS tumour 
classifier.
a, Schematic of principal classifier components (grey) and processing steps for individual 
test samples (white). The most informative probes are selected for training of the Random 
Forest classifier. The classifier produces raw scores representing the number of decision 
trees assigning a test sample to a specific methylation class. To enable inter-class-
comparability a calibration model is used, which transforms raw into calibrated scores. 
Calibrated scores represent an estimated probability measure of methylation class 
assignment. b, Heatmap showing results of a three-fold cross-validation of the Random 
Forest classifier incorporating information of n=2801 biologically independent samples 
allotted to 91 methylation classes. Deviations from the bisecting line represent 
misclassification errors (using the maximum calibrated score for class prediction). 
Methylation class families (MCF) are indicated by black squares. The colour code and 
abbreviations are identical to Figure 1a.
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Figure 3 |. Implementation of the classifier in diagnostic practice.
a, Classifier validation by an independent prospective cohort of diagnostic samples. 
Pathological diagnosis was established by current pathological standard according to the 
2016 version of the WHO classification of CNS tumours and compared to classification by 
methylation profiling. Cases were categorized as “confirmation of diagnosis”, “establishing 
new diagnosis”, “misleading profile”, or “no match to defined class”. b, Overview of 
methylation profiling result from 1,155 diagnostic samples and integration with pathological 
diagnosis.
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Figure 4 |. Reassessment of discrepant cases and establishment of new diagnosis.
Discrepancy between pathological diagnosis (left) and methylation profiling (middle) was 
observed for 139 cases. For 129 cases histological and molecular reassessment 
(Supplementary Table 5) resulted in change of the initial diagnosis with formulation of a 
new integrated diagnosis (right). For 92 cases this involved change of WHO grading, with 
both down- (blue) and upgrading (red). Integrated diagnoses in brackets are not recognized 
as a WHO entity. For methylation class abbreviations see Supplementary Table 1.
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Figure 5 |. DNA methylation-based identification of potential new CNS tumour entities.
a, Unsupervised clustering of the combined reference (n=2,801, grey) and diagnostic cohort 
(n=1,104, coloured) using t-SNE dimensionality reduction. Abbreviated names indicate the 
reference cohort classes as in Figure 1. The diagnostic samples are colour coded as 
“confirmation of diagnosis” (n=838, green), “establishing new diagnosis” (n=129, blue), 
“misleading profile” (n=10, red) and “no match to defined class” (n=127, dark grey). The 
matching (green) and reclassified (blue) cases show high overlap with the reference cases. 
The non-classifiable (black) and the misleading (red) cases frequently fall in the periphery of 
the reference classes or are completely separate of these. The magnification (right) 
highlights two non-classifiable cases (here in magenta for easier identification) that group 
together in the t-SNE representation. b, Both highlighted non-classifiable cases occurred in 
female children, and had primitive neuroectodermal histology (glioblastoma- or embryonal 
tumour-like). Histology was assessed by three independent pathologists with similar results. 
c, Both cases shared a high-level amplification of chromosome 6q24.2 (common amplified 
region chr6:144,149,293–144,649,987). The common region includes only 5 protein coding 
genes: LTV1 (LTV1 ribosome biogenesis factor), ZC2HC1B (zinc finger C2HC-type 
containing 1B), PLAGL1 (PLAG1 like zinc finger 1), SF3B5 (splicing factor 3b subunit 5) 
and STX11 (syntaxin 11). This amplification was not observed in any of the other tumours 
from the reference or diagnostic cohort. Copy number analysis was performed once using 
copy number information deriving from the methylation array data.
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